Global Community Must Do More To Address Rise Of Drug Resistance, Develop New Antibiotics

Washington Post: A new superbug requires urgent attention
Editorial Board

“…Antibiotics are a pillar of modern medicine and have saved lives for decades, but the rise of resistance threatens a back-to-the-future moment when small infections could become fatal, as they once were. This reckoning was postponed for a long time because a robust pipeline of new antibiotics was discovered and brought to market. But then the flow began to dry up. Antibiotics are often not as profitable as other drugs, making costly development less attractive for pharmaceutical companies. The Pew Charitable Trusts and the World Health Organization published analyses in December of the worldwide pipeline of products in clinical development with the potential to treat drug-resistant infections, and they called the findings ‘grim.’ They said too few new antibiotics are under development, and too few represent new classes of drugs. … Just as vital, the overuse of antibiotics in human and animal health must be curbed. Fortunately, there is more attention these days to providing better stewardship of existing drugs. No less is at stake than preserving these miracle medicines, now and for future generations” (2/25).

The KFF Daily Global Health Policy Report summarized news and information on global health policy from hundreds of sources, from May 2009 through December 2020. All summaries are archived and available via search.

KFF Headquarters: 185 Berry St., Suite 2000, San Francisco, CA 94107 | Phone 650-854-9400
Washington Offices and Barbara Jordan Conference Center: 1330 G Street, NW, Washington, DC 20005 | Phone 202-347-5270 | Email Alerts: | |

The independent source for health policy research, polling, and news, KFF is a nonprofit organization based in San Francisco, California.